Toll-like receptor 3 antagonists

Abstract

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

1 . A method of treating or preventing viral infections comprising administering a therapeutically effective amount of an isolated antibody or fragment thereof to a patient in need thereof for a time sufficient to treat or prevent viral infections, wherein the antibody binds toll-like receptor 3 (TLR3) amino acid residues K416, K418, L440, N441, E442, Y465, N466, K467, Y468, R488, R489, A491, K493, N515, N516, N517, H539, N541, S571, L595, and K619 of SEQ ID NO: 2. 
     
     
         2 . A method of treating or preventing viral infections comprising administering a therapeutically effective amount of an isolated antibody or fragment thereof to a patient in need thereof for a time sufficient to treat or prevent viral infections, wherein the isolated antibody comprises a heavy chain variable region and a light chain variable region or fragment thereof and the isolated antibody heavy chain variable region Chothia residues W33, F50, D52, D54, Y56, N58, P61, E95, Y97, Y100, and D100b and the isolated antibody light chain variable region Chothia residues Q27, Y32, N92, T93, L94, and S95 bind toll-like receptor 3 (TLR3) that has the amino acid sequence shown in SEQ ID NO: 2. 
     
     
         3 . The method of  claim 1 , wherein the viral infection is influenza A virus infection. 
     
     
         4 . The method of  claim 2 , wherein the viral infection is influenza A virus infection.